NervGen Pharma Corp. (NGEN) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.37 (-4.86% 1D, market cap $155.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #313 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $155.8M) and DERM (Journey Medical Corporation) posts a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #313 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.3M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While NGEN currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.88) and Max Pain ($1.44) forces dealer call-delta covering toward $6.62.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NervGen Pharma Corp. (NGEN) dropped -4.86% to $1.37, trading at 2% of its 52-week range ($1.35 – $6.3). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Stock Titan report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Streetwise Reports report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in th
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NGEN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NGEN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NervGen Pharma Corp. (NGEN) ranks #313 by composite RQD confidence (49/100, grade D) and #605 by equity capitalization ($155.0M). Within this direct 5-issuer industry benchmark cohort, NGEN leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. ALXO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with NGEN at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NGEN
ACTIVE
NervGen Pharma Corp. | D | 49/100 | — | — | — | -4.86% | $155.0M | Benchmark Subject |
| CUE Cue Biopharma Inc. | E | 33/100 | — | — | -35.0% | -2.70% | $155.8M | /cue-vs-ngen → |
| DERM Journey Medical Corporation | E | 31/100 | — | 65.8% | -19.5% | -4.44% | $152.7M | /derm-vs-ngen → |
| ALXO ALX Oncology Holdings Inc. | D | 50/100 | — | — | -35.0% | 0.00% | $152.4M | /alxo-vs-ngen → |
| MGNX MacroGenics Inc. | E | 31/100 | — | 96.0% | -35.0% | +0.84% | $151.6M | /mgnx-vs-ngen → |
NervGen Pharma Corp. (NGEN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $155.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.37 (-4.86% 1D, market cap $155.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #313 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CUE (Cue Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $155.8M) and DERM (Journey Medical Corporation) posts a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #313 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
NGEN last traded at $1.37 (-4.86% on volume of 546,945 shares), positioning the stock -27.13% below its 50-day simple moving average ($1.88) and -51.42% below its 200-day simple moving average ($2.82). Across its 52-week range of $1.35 to $6.30, NGEN sits at the 0.4% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).
Why NGEN Stock dropped -4.86% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, NGEN scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Taken together, the rating frames NGEN as a stock where the balance sheet is the relative bright spot, while cash generation and institutional/insider signals are weak. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. Upside drivers would need to come from catalysts rather than current fundamentals, and the rating itself flags distribution risk.
The Butterfly supply-chain graph lists no supply chain links and no proprietary signals, so no cross-company signal read-through is available.
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations, which is not sufficient to map ripple effects.
Real-time company headlines, analyst actions, and sector developments for NervGen Pharma Corp. (NGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Streetwise Reports report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Welcome to the NGEN (NervGen Pharma Corp.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on NGEN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless NervGen Pharma Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on NGEN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.44 (52-wk range $1.34 - $1.66), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).